We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+60.76%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$323M
AUM Growth
+$81M
Cap. Flow
+$51.5M
Cap. Flow %
15.94%
Top 10 Hldgs %
43.73%
Holding
97
New
25
Increased
29
Reduced
18
Closed
15

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$15M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$10.5M
3
KRYS icon
Krystal Biotech
KRYS
+$8.67M
4
BIIB icon
Biogen
BIIB
+$4.63M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$4.59M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$7.2M
2
NUVL
Nuvalent
NUVL
+$6.29M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.11M
4
PHVS icon
Pharvaris
PHVS
+$3.48M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.94M

Sector Composition

Rank Sector Weight
1 Healthcare 91.53%
2 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TELA icon
26
TELA Bio
TELA
$30.1M
$4.22M 1.3%
416,440
+362,344
+670% +$3.71M
VKTX icon
27
Viking Therapeutics
VKTX
$3.85B
$4.19M 1.3%
258,595
-121,405
-32% -$2.54M
PRAX icon
28
Praxis Precision Medicines
PRAX
$8.28B
$4M 1.24%
+231,744
New +$3.55M
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.26B
$3.84M 1.19%
99,756
+3,113
+3% +$124K
MRSN
30
CALL
DELISTED
Mersana Therapeutics
MRSN
$3.62M 1.12%
+44,000
New +$6.44M
OLMA icon
31
Olema Pharmaceuticals
OLMA
$995M
$3.53M 1.09%
+390,466
New +$2.36M
SRPT icon
32
Sarepta Therapeutics
SRPT
$1.59B
$3.42M 1.06%
29,860
+20,590
+222% +$2.66M
PRTA icon
33
Prothena Corp
PRTA
$452M
$3.39M 1.05%
+49,721
New +$3.21M
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.3M 1.02%
+91,213
New +$3.76M
MRSN
35
DELISTED
Mersana Therapeutics
MRSN
$3.29M 1.02%
40,000
+18,398
+85% +$2.69M
INSM icon
36
Insmed
INSM
$22.7B
$3.05M 0.94%
144,464
+670
+0.5% +$12.7K
PHVS icon
37
Pharvaris
PHVS
$2.34B
$3.03M 0.94%
200,000
-359,387
-64% -$3.48M
ANIP icon
38
ANI Pharmaceuticals
ANIP
$1.81B
$2.91M 0.9%
+54,041
New +$2.4M
PHAT icon
39
Phathom Pharmaceuticals
PHAT
$959M
$2.86M 0.89%
200,000
– –
CERS icon
40
Cerus
CERS
$589M
$2.85M 0.88%
1,158,265
+5,363
+0.5% +$12.7K
MIRM icon
41
Mirum Pharmaceuticals
MIRM
$6.89B
$2.75M 0.85%
106,375
+436
+0.4% +$11.6K
ACRS icon
42
Aclaris Therapeutics
ACRS
$732M
$2.27M 0.7%
219,229
-871
-0.4% -$7.88K
INCY icon
43
Incyte
INCY
$24.9B
$2.12M 0.66%
34,110
+172
+0.5% +$11.5K
TRVI icon
44
Trevi Therapeutics
TRVI
$2.57B
$2.12M 0.66%
885,924
– –
NTLA icon
45
Intellia Therapeutics
NTLA
$1.42B
$2.07M 0.64%
50,858
+13,000
+34% +$527K
PLRX icon
46
Pliant Therapeutics
PLRX
$68.1M
$1.94M 0.6%
107,267
+7,267
+7% +$172K
RYTM icon
47
Rhythm Pharmaceuticals
RYTM
$7.48B
$1.92M 0.59%
+116,168
New +$2.1M
CBAY
48
DELISTED
Cymabay Therapeutics
CBAY
$1.75M 0.54%
+160,000
New +$1.49M
AMAM
49
DELISTED
Ambrx Biopharma Inc
AMAM
$1.65M 0.51%
+100,000
New +$1.26M
CUE icon
50
Cue Biopharma
CUE
$131M
$1.47M 0.46%
13,447
+3,238
+32% +$381K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Silverarc Capital Management held 97 positions worth $323M, up 33% from $242M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $51.5M of net new capital in Q2 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Nuvalent, an estimated $6.29M trimmed.

  • Silverarc Capital Management's largest Q2 2023 buy was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.
  • Silverarc Capital Management added most to Immunogen Inc in Q2 2023, an estimated $15M increase.
  • Silverarc Capital Management's biggest Q2 2023 reduction was Nuvalent, cutting an estimated $6.29M.
  • Silverarc Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $7.2M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $323M portfolio in Q2 2023.
  • Silverarc Capital Management opened 25 new positions and closed 15 in Q2 2023.
  • Silverarc Capital Management's portfolio value rose 33% quarter-over-quarter to $323M.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.